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Abstract
Cardiac amyloidosis is caused by abnormal deposit of amyloid in the myocardium and can be divided into light chain
(AL) amyloidosis and transthyretin (ATTR) amyloidosis. ATTR amyloidosis can be further divided into wild-type and
mutant type based on genetic mutation. Differentiation between AL, wild-type, and mutant type ATTR amyloidosis has
signiﬁcant prognostic and therapeutic implications.
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1. Introduction

W

aldenstrom macroglobulinemia (WM) is a
rare disease characterized by lymphoplasmacytic lymphoma in the bone marrow and
immunoglobulin M (IgM) monoclonal gammopathy
in the blood, it is uncommonly associated with AL
amyloidosis and rarely with wild type ATTR
amyloidosis. There has been no reported case of
concurrent WM and mutant ATTR (mATTR) cardiac
amyloidosis.

2. Case presentation
A 76-year-old African American male with medical history of chronic kidney disease stage 3 presented to urgent care with one month of dyspnea on
exertion and orthopnea. Vitals signs were normal
and physical exam was remarkable for rales in
bilateral lungs and 1þ pitting edema of bilateral
legs. Initial laboratory work was signiﬁcant for
troponin of 0.13 ng/ml (reference range 0.07 ng/
ml) and B type natriuretic peptide (BNP) of 552 pg/
ml (reference range 100 pg/ml). Electrocardiogram
(ECG) indicated new atrial ﬁbrillation and low
voltage QRS (Fig. 1). Chest X-ray showed

cardiomegaly and small bilateral pleural effusion.
Patient was given furosemide 40 mg intravenously
and observed in urgent care for 6 h. His shortness of
breath improved with diuresis, and he was discharged home.
Patient was seen by cardiologist the next day. An
echocardiography was obtained and showed signiﬁcant left ventricular hypertrophy (LVH) (Fig. 2)
and global hypokinesis with left ventricular ejection
fraction of 35%. Exercise myocardial perfusion test
did not show any reversible ischemia. The clinical
suspicion for inﬁltrative cardiomyopathy was high
given elevated BNP and troponin, low voltage QRS
on ECG, new onset atrial ﬁbrillation as well as LVH
on echocardiogram. Serum and urine studies were
obtained to evaluate for inﬁltrative cardiomyopathy.
Serum electrophoresis showed M-spike migrating
in the gamma globulin region. Urine electrophoresis
was positive for free light chains with Kappa light
chain of 148.41 mg/L (reference range 32.90 mg/L),
Lambda light chain of 19.39 mg/L (reference range
3.79 mg/L), and a Kappa to Lamda ratio of 7.65
(abnormal 1.65). Serum and urine immunoﬁxation
demonstrated IgM Kappa monoclonal band.
Abdominal fat pad biopsy was negative for
amyloidosis. Bone marrow biopsy found low grade
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Fig. 1. Electrocardiogram showed atrial ﬁbrillation, left axis deviation and low voltage QRS.

B-cell neoplasm, in the setting of IgM Kappa
monoclonal gammopathy this was highly suspicious
for WM. Genetic testing found MYD88 L265P gene
mutation, which conﬁrmed the diagnosis of WM.
A cardiac magnetic resonance imaging was obtained given continued suspicion of cardiac

amyloidosis (CA) despite negative bone marrow
and abdominal fat pad biopsy, and it demonstrated
diffuse subendocardial enhancement with areas of
mid-myocardial enhancement (Fig. 3), which was
consistent with CA. Endomyocardial biopsy was
proceeded. Hematoxylin and eosin staining of

Fig. 2. Echocardiogram indicated signiﬁcant left ventricular hypertrophy, mildly thickened mitral and tricuspid valve leaﬂets, and small pericardial
effusion.
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Fig. 3. Cardiac magnetic resonance demonstrated (A) Cine images with left ventricular hypertrophy; (B) Late gadolinium enhancement with diffuse
gadolinium enhancement of myocardium; (C) Phase sensitive inversion recovery showed diffuse myocardial gadolinium enhancement.

endomyocardial biopsy samples showed Congo
red-positive amyloid deposits (Fig. 4). Liquid
chromatographyemass spectrometry (LC MS/MS)
of peptides extracted from Congo red-positive
specimen detected a peptide proﬁle consistent with
ATTR type amyloid deposition. LC MS/MS also

detected an amino acid sequence abnormality
Val142IIe in the TTR protein. Formal genetic testing
conﬁrmed Val142IIe pathogenic mutation.
Patient was started on tafamidis 61 mg daily for
ATTR amyloidosis. His ﬁrst-degree relatives were
advised to have genetic testing. No treatment for

Fig. 4. Endomyocardial biopsy A. Congo red staining showed amyloid deposits (red arrow); B. Amyloids deposits in ﬂuorescent green (green arrow).
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WM was initiated and he was recommended to
follow up with hematologist regularly.

3. Discussion
WM is a rare disorder with an incidence of 3.4
cases per million per year in males in the United
States and 1.7 cases per million per year in females.
Median age at presentation is about 70 years old.
WM are predominantly found in Americans of European descent with African Americans representing only 5% of patients.1 About a quarter of patients
with WM have no symptoms or anemia attributable
to IgM monoclonal protein inﬁltration. These patients are considered to have smoldering WM and
do not need treatment. One of the indications for
treatment is AL amyloidosis.
CA is caused by abnormal deposit of amyloid in
the myocardium, and it can present with atrial
ﬁbrillation, heart failure as well as conduction disorders. The subtypes of CA include AL, wide type
ATTR and mATTR amyloidosis. Val142lle is the
most common mutation seen in patients with
mATTR amyloidosis. Among patients of African
American descent, the reported prevalence of
Val142IIe is 1.1e9.8% while in the general population this ranges from 0.3 to 1.6%. Typically,
Val142IIe variant ATTR amyloidosis presents in the
seventh to eighth decade of life.2 With the
advancement of noninvasive diagnostic methods,
especially Technetium-99m Pyrophosphate scintigraphy (99mTc-PYP), ATTR amyloidosis can be diagnosed without endomyocardial biopsy.3 However, a
positive PYP scan in patients with plasma cell
dyscrasia does not exclude AL amyloidosis, as in
rare cases AL amyloidosis and ATTR amyloidosis
can coexist.4 The sensitivity of abdominal fat pad
biopsy for detecting AL, mATTR and wild type
ATTR amyloidosis was only estimated to be 84%,
45% and 15%, respectively.5 In patients with suspected CA and abnormal free light chains on
immunoﬁxation, endomyocardial biopsy is the only
method to make deﬁnitive conclusion.
AL amyloidosis complicates about 3% of WM
cases based on previous studies.6,7 Patients with AL
amyloidosis and WM have higher tendency for
amyloid-associated cardiomyopathy compared to
other AL cases.7 However, CA in patients with WM
is not always AL amyloidosis, case series have
demonstrated that WM can coexist with wild type
ATTR amyloidosis,8 especially as both diseases
primarily affect the elderly population. Differentiation between AL and ATTR amyloidosis has significant prognostic and therapeutic implications.
Patients with WM and AL CA have a shorter life

expectancy compared to patients without CA and
treatment focuses on the underlying hematological
disease.6 Treatment of ATTR amyloidosis, on the
other hand, focuses on preventing further accumulation of the transthyretin protein, primarily with
tafamidis, a small molecule which stabilizes transthyretin tetramers. The ATTR-ACT study showed
mortality and morbidity beneﬁt of tafamidis in
treatment of ATTR cardiomyopathy and the recently
published long-term outcome data again conﬁrmed
the signiﬁcant survival beneﬁt.9,10
Patient has been doing well from cardiac as well as
hematological standpoints 12 months after diagnosis.

4. Conclusion
To our best knowledge, to this date there has been
no case reported with concurrent WM and mATTR
amyloidosis. This case highlights the importance to
keep all types of cardiac amyloidosis in differential
diagnoses and to perform endomyocardial biopsy in
patients with plasma cell dyscrasia to conﬁrm the
diagnosis.
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